Adam Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Wright has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Christopher E. Brightling
Institute for Lung Health, National Institute for Health and Care Research, Leicester Biomedical Research Centre, University of Leicester, Leicester, UK
8 shared publications - Neil J. Greening
The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK
4 shared publications Hnin Aung
Department of Respiratory Sciences, University of Leicester, Leicester, UK
3 shared publicationsMatthew Richardson
Department of Respiratory Sciences, University of Leicester, UK
3 shared publicationsTracy Thornton
Institute for Lung Health, NIHR Respiratory Biomedical Research Centre, University Hospitals of Leicester, Leicester, UK
3 shared publications- Cara Flynn
Department of Respiratory Sciences, University of Leicester, Leicester, UK
2 shared publications
Latest Publications
- Open Access
- 1 October 2024
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (174) , 240136
Digital remote maintenance inhaler adherence interventions in COPD: a systematic review and meta-analysis
Introduction: Sub-optimal inhaler adherence undermines the efficacy of pharmacotherapy in COPD. Digitalised care pathways are increasingly used to improve inhaler-use behaviour remotely. This review investigated the feasibility and impact of remote electronic inhaler adherence monitoring (EIM) and intervention platforms on clinical outcomes in COPD.Methods: A literature search was conducted and studies investigating maintenance inhaler use among people with COPD using digital technology were selected. Pairwise and proportional meta-analyses were employed with heterogeneity assessed using I2statistics. When meta-analysis was not feasible, a narrative synthesis of outcomes was conducted.Results: We included 10 studies including 1432 people with COPD whose maintenance inhaler usage was supported by digital inhalers and apps featuring audiovisual reminders and educational content with or without engagement with healthcare providers (HCPs). Inhaler adherence rate (AR) varied with calculation methods, but an overall suboptimal adherence was observed among people with COPD. HCP-led adherence interventions alongside EIM improved mean AR by 18% (95% CI 9–27)versuspassive EIM only. Enhanced AR may reduce COPD-related healthcare utilisation with little impact on health-related quality of life and exacerbation rate. Despite encountering technical issues among 14% (95% CI 5–23%) of participants, 85% (95% CI 76–94%) found digital platforms convenient to use, while 91% (95% CI 79–100%) perceived inhaler reminders as helpful.Conclusion: Digitalised interventions can enhance maintenance inhaler adherence in COPD but their overall effect on clinical outcomes remains uncertain. Further work is required to tailor interventions to individuals’ adherence behaviour and investigate their longer-term impact.
- 1 October 2024
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (174) , 240136
Open AccessDigital remote maintenance inhaler adherence interventions in COPD: a systematic review and meta-analysis
Introduction: Sub-optimal inhaler adherence undermines the efficacy of pharmacotherapy in COPD. Digitalised care pathways are increasingly used to improve inhaler-use behaviour remotely. This review investigated the feasibility and impact of remote electronic inhaler adherence monitoring (EIM) and intervention platforms on clinical outcomes in COPD.Methods: A literature search was conducted and studies investigating maintenance inhaler use among people with COPD using digital technology were selected. Pairwise and proportional meta-analyses were employed with heterogeneity assessed using I2statistics. When meta-analysis was not feasible, a narrative synthesis of outcomes was conducted.Results: We included 10 studies including 1432 people with COPD whose maintenance inhaler usage was supported by digital inhalers and apps featuring audiovisual reminders and educational content with or without engagement with healthcare providers (HCPs). Inhaler adherence rate (AR) varied with calculation methods, but an overall suboptimal adherence was observed among people with COPD. HCP-led adherence interventions alongside EIM improved mean AR by 18% (95% CI 9–27)versuspassive EIM only. Enhanced AR may reduce COPD-related healthcare utilisation with little impact on health-related quality of life and exacerbation rate. Despite encountering technical issues among 14% (95% CI 5–23%) of participants, 85% (95% CI 76–94%) found digital platforms convenient to use, while 91% (95% CI 79–100%) perceived inhaler reminders as helpful.Conclusion: Digitalised interventions can enhance maintenance inhaler adherence in COPD but their overall effect on clinical outcomes remains uncertain. Further work is required to tailor interventions to individuals’ adherence behaviour and investigate their longer-term impact.
- Open Access
- 27 June 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (5)
Post-pandemic seasonal dynamics of hospitalised COPD exacerbations and aetiologies in the COPD population
The impact of seasonality on the morbidity due to acute exacerbations of COPD (AECOPD) is well recognised, with winter months typically associated with increased respiratory infections and healthcare utilisation among the COPD population [1]. The first wave of the coronavirus disease 2019 (COVID-19) pandemic saw at least 50% decline in AECOPD admissions associated with fewer viral triggers [2]. However, after relaxation of lockdown measures, it is unknown if there has been a longer-term shift in the seasonal pattern of AECOPD hospitalisations and their specific aetiologies, considering the heterogeneity behind exacerbations. This information may help healthcare providers prepare targeted preventative measures and resource allocation.
- 27 June 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (5)
Open AccessPost-pandemic seasonal dynamics of hospitalised COPD exacerbations and aetiologies in the COPD population
The impact of seasonality on the morbidity due to acute exacerbations of COPD (AECOPD) is well recognised, with winter months typically associated with increased respiratory infections and healthcare utilisation among the COPD population [1]. The first wave of the coronavirus disease 2019 (COVID-19) pandemic saw at least 50% decline in AECOPD admissions associated with fewer viral triggers [2]. However, after relaxation of lockdown measures, it is unknown if there has been a longer-term shift in the seasonal pattern of AECOPD hospitalisations and their specific aetiologies, considering the heterogeneity behind exacerbations. This information may help healthcare providers prepare targeted preventative measures and resource allocation.
- Open Access
- 6 March 2024
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2323706
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
Antibodies are one of the most important reagents used in biomedical and fundamental research, used to identify, and quantify proteins, contribute to knowledge of disease mechanisms, and validate drug targets. Yet many antibodies used in research do not recognize their intended target, or recognize additional molecules, compromising the integrity of research findings and leading to waste of resources, lack of reproducibility, failure of research projects, and delays in drug development. Researchers frequently use antibodies without confirming that they perform as intended in their application of interest. Here we argue that the determinants of end-user antibody choice and use are critical, and under-addressed, behavioral drivers of this problem. This interacts with the batch-to-batch variability of these biological reagents, and the paucity of available characterization data for most antibodies, making it more difficult for researchers to choose high quality reagents and perform necessary validation experiments. The open-science company YCharOS works with major antibody manufacturers and knockout cell line producers to characterize antibodies, identifying high-performing renewable antibodies for many targets in neuroscience. This shows the progress that can be made by stakeholders working together. However, their work so far applies to only a tiny fraction of available antibodies. Where characterization data exists, end-users need help to find and use it appropriately. While progress has been made in the context of technical solutions and antibody characterization, we argue that initiatives to make best practice behaviors by researchers more feasible, easy, and rewarding are needed. Global cooperation and coordination between multiple partners and stakeholders will be crucial to address the technical, policy, behavioral, and open data sharing challenges. We offer potential solutions by describing our Only Good Antibodies initiative, a community of researchers and partner organizations working toward the necessary change. We conclude with an open invitation for stakeholders, including researchers, to join our cause.
- 6 March 2024
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2323706
Open AccessImproving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
Antibodies are one of the most important reagents used in biomedical and fundamental research, used to identify, and quantify proteins, contribute to knowledge of disease mechanisms, and validate drug targets. Yet many antibodies used in research do not recognize their intended target, or recognize additional molecules, compromising the integrity of research findings and leading to waste of resources, lack of reproducibility, failure of research projects, and delays in drug development. Researchers frequently use antibodies without confirming that they perform as intended in their application of interest. Here we argue that the determinants of end-user antibody choice and use are critical, and under-addressed, behavioral drivers of this problem. This interacts with the batch-to-batch variability of these biological reagents, and the paucity of available characterization data for most antibodies, making it more difficult for researchers to choose high quality reagents and perform necessary validation experiments. The open-science company YCharOS works with major antibody manufacturers and knockout cell line producers to characterize antibodies, identifying high-performing renewable antibodies for many targets in neuroscience. This shows the progress that can be made by stakeholders working together. However, their work so far applies to only a tiny fraction of available antibodies. Where characterization data exists, end-users need help to find and use it appropriately. While progress has been made in the context of technical solutions and antibody characterization, we argue that initiatives to make best practice behaviors by researchers more feasible, easy, and rewarding are needed. Global cooperation and coordination between multiple partners and stakeholders will be crucial to address the technical, policy, behavioral, and open data sharing challenges. We offer potential solutions by describing our Only Good Antibodies initiative, a community of researchers and partner organizations working toward the necessary change. We conclude with an open invitation for stakeholders, including researchers, to join our cause.
- Open Access
- 28 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (4) , 2301125
Differences in hospital admissions for acute exacerbations of COPD during the COVID-19 pandemic stratified by stable-state blood eosinophil count
Acute exacerbations of COPD (AECOPD) are driven through different triggers, including infection such as viruses and bacteria. However, nearly 40% of exacerbations are associated with a blood eosinophilia and related to type 2 inflammation (T2-high) [1].
- 28 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (4) , 2301125
Open AccessDifferences in hospital admissions for acute exacerbations of COPD during the COVID-19 pandemic stratified by stable-state blood eosinophil count
Acute exacerbations of COPD (AECOPD) are driven through different triggers, including infection such as viruses and bacteria. However, nearly 40% of exacerbations are associated with a blood eosinophilia and related to type 2 inflammation (T2-high) [1].
- Open Access
- 1 May 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (Supplement) , 250.15
Characterization of germinal center and circulating T follicular helper cells using both intracellular and surface CITE-seq
T follicular helper (TFH) cells are a CD4+ T cell subset that play a critical role in the formation of germinal centers (GC). TFH cells are essential to produce protective antibody responses through regulation of clonal selection & differentiation into activated antibody-secreting & memory B cells. TFH cell differentiation is a multistep process that begins with presentation of antigen by dendritic cells to naïve CD4+ T cells, where CD4+ T cells commit to the TFH lineage by expressing the lineage defining transcription factor B cell lymphoma 6 (Bcl-6). TFH cells are phenotypically characterized by high expression of C-X-C chemokine receptor 5 (CXCR5) & programmed cell death-1 (PD-1) on the cell surface. CXCR5+ memory CD4+ T cells present in peripheral blood represent a circulating TFH (cTFH) cell subset. In contrast to TFH cells, cTFH cells may express low levels of Bcl-6 with numerous reports of subsets that differ both phenotypically & functionally. Here we characterise the heterogeneous subsets of TFH & cTFH cells using a combination of intracellular CITE-seq, surface CITE-seq and whole transcriptome single-cell RNA sequencing (scRNA-seq) analysis. Germinal center and circulating TFH cells were enriched by sorting memory CD4+, CXCR5+, PD-1+, and memory CD4+ CXCR5+ cells, respectively. We examined the expression of Bcl-6 & other transcription factors, using protein and RNA expression data, across pre-TFH, TFH & cTFH cells. Together, these data demonstrate how a combination of intracellular CITE-seq, surface CITE-seq & scRNA-seq may be used to deepen our understanding of the differentiation states & subsets of cells present at low abundance, by enabling detection of intracellular and surface protein along with high-quality mRNA.
- 1 May 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (Supplement) , 250.15
Open AccessCharacterization of germinal center and circulating T follicular helper cells using both intracellular and surface CITE-seq
T follicular helper (TFH) cells are a CD4+ T cell subset that play a critical role in the formation of germinal centers (GC). TFH cells are essential to produce protective antibody responses through regulation of clonal selection & differentiation into activated antibody-secreting & memory B cells. TFH cell differentiation is a multistep process that begins with presentation of antigen by dendritic cells to naïve CD4+ T cells, where CD4+ T cells commit to the TFH lineage by expressing the lineage defining transcription factor B cell lymphoma 6 (Bcl-6). TFH cells are phenotypically characterized by high expression of C-X-C chemokine receptor 5 (CXCR5) & programmed cell death-1 (PD-1) on the cell surface. CXCR5+ memory CD4+ T cells present in peripheral blood represent a circulating TFH (cTFH) cell subset. In contrast to TFH cells, cTFH cells may express low levels of Bcl-6 with numerous reports of subsets that differ both phenotypically & functionally. Here we characterise the heterogeneous subsets of TFH & cTFH cells using a combination of intracellular CITE-seq, surface CITE-seq and whole transcriptome single-cell RNA sequencing (scRNA-seq) analysis. Germinal center and circulating TFH cells were enriched by sorting memory CD4+, CXCR5+, PD-1+, and memory CD4+ CXCR5+ cells, respectively. We examined the expression of Bcl-6 & other transcription factors, using protein and RNA expression data, across pre-TFH, TFH & cTFH cells. Together, these data demonstrate how a combination of intracellular CITE-seq, surface CITE-seq & scRNA-seq may be used to deepen our understanding of the differentiation states & subsets of cells present at low abundance, by enabling detection of intracellular and surface protein along with high-quality mRNA.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , RCT206
Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory airways disease. The epithelial-derived ‘alarmin’ IL-33 and its receptor ST2 have been implicated in airway inflammation and infection. We sought to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. Methods: We undertook a single-centre, randomised, double-blinded, placebo-controlled, phase IIa trial in moderate-to-very severe COPD. Participants received astegolimab 490mg (n=42) or placebo (n=39), every 4 weeks over 44 weeks. Primary endpoint was exacerbation rate over 48 weeks with pre-specified subgroup analysis by baseline blood eosinophil count. Secondary endpoints included Saint George’s Respiratory Questionnaire for COPD (SGRQ-C), FEV1, blood and sputum cell counts, and safety and tolerability. Results: The 48-week exacerbation rate in the astegolimab group relative to placebo was 0.78 (0.53 -0 1.14; p=0.195) in the whole group and 0.69 (0.39 - 1.21) and 0.83 (0.49 - 1.40) in subjects below or above the median baseline blood eosinophil count (170 cells/µL). In the astegolimab group versus placebo the mean difference for SGRQ-C and FEV1 was –3.3 (-6.4 to -0.2; p=0.039) and 40ml (-10 to 90; p=0.094), respectively. The differences in geometric mean ratios for blood and sputum eosinophil counts were 0.59 (0.51 - 0.69; p<0.001) and 0.25 (0.19 - 0.33; p<0.001). Incidence of treatment-emergent adverse events was similar between groups. Conclusion: Astegolimab did not reduce 48-week COPD exacerbation rate significantly in the whole group, subgroup analyses suggested more benefit in subjects with lower blood eosinophil counts.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , RCT206
Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory airways disease. The epithelial-derived ‘alarmin’ IL-33 and its receptor ST2 have been implicated in airway inflammation and infection. We sought to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. Methods: We undertook a single-centre, randomised, double-blinded, placebo-controlled, phase IIa trial in moderate-to-very severe COPD. Participants received astegolimab 490mg (n=42) or placebo (n=39), every 4 weeks over 44 weeks. Primary endpoint was exacerbation rate over 48 weeks with pre-specified subgroup analysis by baseline blood eosinophil count. Secondary endpoints included Saint George’s Respiratory Questionnaire for COPD (SGRQ-C), FEV1, blood and sputum cell counts, and safety and tolerability. Results: The 48-week exacerbation rate in the astegolimab group relative to placebo was 0.78 (0.53 -0 1.14; p=0.195) in the whole group and 0.69 (0.39 - 1.21) and 0.83 (0.49 - 1.40) in subjects below or above the median baseline blood eosinophil count (170 cells/µL). In the astegolimab group versus placebo the mean difference for SGRQ-C and FEV1 was –3.3 (-6.4 to -0.2; p=0.039) and 40ml (-10 to 90; p=0.094), respectively. The differences in geometric mean ratios for blood and sputum eosinophil counts were 0.59 (0.51 - 0.69; p<0.001) and 0.25 (0.19 - 0.33; p<0.001). Incidence of treatment-emergent adverse events was similar between groups. Conclusion: Astegolimab did not reduce 48-week COPD exacerbation rate significantly in the whole group, subgroup analyses suggested more benefit in subjects with lower blood eosinophil counts.
- Open Access
- 1 June 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 1177-1185
Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and Streptococcus pneumoniae were reduced following treatment with benralizumab. However, in vitro, eosinophils did not affect the killing of the common airway pathogens S. pneumoniae or Haemophilus influenzae. Thus, benralizumab may have an indirect effect upon airway bacterial load.
- 1 June 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 1177-1185
Open AccessSputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and Streptococcus pneumoniae were reduced following treatment with benralizumab. However, in vitro, eosinophils did not affect the killing of the common airway pathogens S. pneumoniae or Haemophilus influenzae. Thus, benralizumab may have an indirect effect upon airway bacterial load.
- Open Access
- 1 November 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1430-1433.e4
Human group 2 innate lymphoid cells do not express the IL-5 receptor
- 1 November 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1430-1433.e4
Open AccessHuman group 2 innate lymphoid cells do not express the IL-5 receptor
Myeloid-derived suppressor cell-like fibrocytes are increased and associated with preserved lung function in chronic obstructive pulmonary disease
The role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown. We sought to enumerate blood and tissue fibrocytes in COPD and determine the association of blood fibrocytes with clinical features of disease. Utilizing flow cytometry to identify circulating, collagen type 1+ cells, we found two populations: (i) CD45+ CD34+ (fibrocytes) and (ii) CD45+ CD34− [myeloid-derived suppressor cell (MDSC)-like fibrocytes] cells in stable COPD (n = 41) and control (n = 29) subjects. Lung resection material from a separate group of subjects with (n = 11) or without (n = 11) COPD was collected for tissue fibrocyte detection. We examined circulating fibrocyte populations for correlations with clinical parameters including quantitative computed tomography (qCT) and determined pathways of association between correlated variables using a path analysis model. Blood and tissue fibrocytes were not increased compared to control subjects nor were blood fibrocytes associated with lung function or qCT, but were increased in eosinophilic COPD. Myeloid-derived suppressor cell-like fibrocytes were increased in COPD compared to controls [2.3 (1.1–4.9), P = 0.038]. Our path analysis model showed that collagen type 1 intensity for MDSC-like fibrocytes was positively associated with lung function through associations with air trapping, predominately in the upper lobes. We have demonstrated that two circulating populations of fibrocyte exist in COPD, with distinct clinical associations, but are not prevalent in proximal or small airway tissue. Blood MDSC-like fibrocytes, however, are increased and associated with preserved lung function through a small airway-dependent mechanism in COPD.
Myeloid-derived suppressor cell-like fibrocytes are increased and associated with preserved lung function in chronic obstructive pulmonary disease
The role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown. We sought to enumerate blood and tissue fibrocytes in COPD and determine the association of blood fibrocytes with clinical features of disease. Utilizing flow cytometry to identify circulating, collagen type 1+ cells, we found two populations: (i) CD45+ CD34+ (fibrocytes) and (ii) CD45+ CD34− [myeloid-derived suppressor cell (MDSC)-like fibrocytes] cells in stable COPD (n = 41) and control (n = 29) subjects. Lung resection material from a separate group of subjects with (n = 11) or without (n = 11) COPD was collected for tissue fibrocyte detection. We examined circulating fibrocyte populations for correlations with clinical parameters including quantitative computed tomography (qCT) and determined pathways of association between correlated variables using a path analysis model. Blood and tissue fibrocytes were not increased compared to control subjects nor were blood fibrocytes associated with lung function or qCT, but were increased in eosinophilic COPD. Myeloid-derived suppressor cell-like fibrocytes were increased in COPD compared to controls [2.3 (1.1–4.9), P = 0.038]. Our path analysis model showed that collagen type 1 intensity for MDSC-like fibrocytes was positively associated with lung function through associations with air trapping, predominately in the upper lobes. We have demonstrated that two circulating populations of fibrocyte exist in COPD, with distinct clinical associations, but are not prevalent in proximal or small airway tissue. Blood MDSC-like fibrocytes, however, are increased and associated with preserved lung function through a small airway-dependent mechanism in COPD.